Sat Sep 21 11:35:04 UTC 2024: ## Torrent Pharma’s Strong Growth Fuels Valuation Premium

**Mumbai, India:** Torrent Pharmaceuticals has successfully integrated its acquisition of Curatio, with the newly acquired company now contributing to the company’s growth. The integration has been a key driver behind Torrent Pharma’s impressive 78% stock rally over the past year, outperforming the Nifty Pharma index’s 48% growth.

Analysts predict continued strong top-line growth and margin expansion, resulting in high earnings growth for the company. However, this strong performance has already factored into Torrent Pharma’s valuation, currently trading at 49 times one-year forward earnings, exceeding its historical average of 35 times. As a result, analysts recommend investors hold existing positions in the stock, while new investors are advised to wait for a more favorable entry point.

Torrent Pharma’s strong growth is fueled by its diverse portfolio, with 73% of revenue derived from branded generics sold primarily in India, Brazil, Germany, and the US. The company’s Indian segment has seen impressive 15% revenue CAGR in FY22-24, driven by the integration of Curatio and continued growth in the Indian pharma market. While the company expects to reap further benefits from the acquisition in FY25, its expanded sales force is also focused on increasing market share in existing categories and launching new products.

Torrent Pharma is expanding its operations in Brazil, Germany, and the US. Its Brazil operations are expected to see strong growth in CNS, cardio, and diabetes therapeutic areas. In Germany, the company is leveraging its cost competitiveness to secure contracts in the tender market. The US segment is poised for a return to growth in FY25, driven by planned launches and the recent clearance of its Dahej plant by the US FDA.

The company’s EBITDA margins have improved significantly, reaching 31.4% in FY24, driven by pricing power and lower API costs. Further margin improvement is expected in the coming years. Torrent Pharma has also successfully de-levered its balance sheet since the Curatio acquisition, with its leverage now at 0.65 times compared to 1.2 times before the deal.

Overall, Torrent Pharma’s strong performance and strategic expansion, coupled with improved margins and a de-leveraged balance sheet, make it a strong performer in the pharmaceutical sector. While the current valuation reflects the company’s positive outlook, new investors are advised to wait for a more attractive entry point, while existing investors can hold their positions.

Read More